

April 21, 2025

Chairman Tom Cole  
2207 Rayburn House Office Building  
Washington, DC 20515

Senator Susan Collins  
413 Dirksen Senate Office Building  
Washington, DC 20510

Ranking Member Rosa DeLauro  
2413 Rayburn House Office Building  
Washington, DC 20515

Senator Patty Murray  
154 Russell Senate Office Building  
Washington, DC 20510

Chairman Mario Diaz-Balart  
374 Cannon House Office Building  
Washington, DC 20515

Senator Lindsey Graham  
211 Russell Senate Office Building  
Washington, DC 20510

Ranking Member Lois Frankel  
2305 Rayburn House Office Building  
Washington, DC 20515

Senator Brian Schatz  
722 Hart Senate Office Building  
Washington, DC 20510

Dear Chairman Cole, Ranking Member DeLauro, Chairman Diaz-Balart, Ranking Member Frankel, Senator Collins, Senator Murray, Senator Graham and Senator Schatz,

As representatives of leading American and global companies, we commend your continued support for and prioritization of global health assistance. Not only do these programs save lives and enhance America's safety, security and standing in the world, but they also build healthier, stronger economies that benefit American businesses and other global companies that invest in the U.S. economy. Among the most important—and effective—of these programs is the Global Fund to Fight AIDS, Tuberculosis and Malaria. As the Global Fund begins its three-year replenishment drive, we urge you to allocate a robust contribution in fiscal year 2026.

Since its inception in 2002, the Global Fund partnership has saved over 65 million lives and reduced the combined death rate of HIV/AIDS, tuberculosis and malaria by 63%. Just in 2023, the Global Fund partnership provided life-saving antiretroviral therapy for HIV to 25 million people and essential HIV prevention services for 17.9 million more, treated 7.1 million people for TB and distributed 227 million mosquito nets to protect families from malaria. Since day one, the private sector has played a crucial role in the Global Fund's success, making its programs more efficient and innovative, participating in its governance and contributing funding.

This unique public-private partnership would not be possible without U.S. leadership. As an investment, the Global Fund delivers world-changing returns:

- ***Strengthening economies:*** Strong, resilient and self-sustaining health systems create better opportunities for U.S. trade and investment. Healthy populations mean productive workforces, prosperous consumers and stable business operating environments. The Global Fund invests in strengthening health systems—and helps countries take responsibility for

funding and managing them—which supports long-term economic stability, directly benefiting U.S. interests.

- **Investing in American prosperity:** Since 2010, the Global Fund has invested \$3.5 billion in American companies to procure goods and services like HIV medicines and advanced TB diagnostic tools. Through its market shaping strategy, the Global Fund works with the private sector to incentivize innovation with its large-scale procurement, while making health commodities more affordable and accessible to the most vulnerable.
- **Investing in a safe, secure America:** The Global Fund’s capacity to fight longstanding and emerging pandemics in low- and middle-income keeps Americans safe from infectious disease threats. The Global Fund helps stabilize dozens of geopolitical and conflict hotspots, serving U.S. security interests.
- **Catalyzing burden-sharing:** For every \$1 invested by the U.S. in the Global Fund, international donors match it with \$2, amplifying the impact of our leadership. By law, the U.S. has never contributed more than 33% of the Global Fund’s total resources, so strong U.S. contributions have propelled other donors to step up, too. Global Fund policies, further strengthened in 2024, require countries receiving Global Fund grants to spend more on health programs.
- **Proven results:** Studies show that 53% of the increase in life expectancy—from 49 years to 61 years—across 15 countries in sub-Saharan Africa between 2002 and 2021 can be attributed to progress in fighting HIV, TB and malaria, driven by the Global Fund partnership. Fully funding the Global Fund’s eighth replenishment will save 23 million lives between 2027 and 2029, reduce the combined mortality rate by another 64% relative to 2023 levels and prevent around 400 million infections.
- **Value for money:** The Global Fund makes sure every dollar invested goes as far as possible. Its overhead costs are just 6.2% of its resources, below most comparable organizations. The Global Fund also works with manufacturers to secure better prices on the health commodities it procures, such as negotiating a 25% price reduction on the preferred first-line HIV treatment last year—savings for low-income countries and the U.S. taxpayer alike.

As members of the private sector, we are focused on identifying smart investments. A bold contribution to the Global Fund in FY2026 will save even more lives, advance American economic interests and incentivize other countries to share the financial burden. These effects are proven. We look forward to your continued support.

Sincerely,

Gilead Sciences

Qure.ai

Viatriis

Hetero Labs

(RED)

ViiV Healthcare

IQVIA

SC Johnson and Son, Inc.

Zenysis

Merck

Thermo Fisher Scientific

Nexleaf Analytics

Vestergaard